Payment overview · 2025
General Payments
$10,480.28
16 reported records · 3 companies
Healthcare provider profile · identity verified
Francisco Manuel Murphy-Rivera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ADJUNTAS, PR · NPI 1770572018
Verified facts
What the public records show
CMS Open Payments records show Francisco Manuel Murphy-Rivera, MD received $10,480.28 in general payments during 2025 across 16 reported records.
GlaxoSmithKline, LLC. accounted for 98.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $10,276.08 | 98.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.15 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.05 | 0.9% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,000.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,000.00 | 2 |
| Travel and Lodging | $975.14 | 4 |
| Food and Beverage | $505.14 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $5,000.00 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $4,296.67 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $204.20 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 116 |
| Famotidine | Famotidine | 731 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 72 |
| Metformin Hcl | Metformin Hcl | 377 | 63 |
| Lisinopril | Lisinopril | 301 | 46 |
| Omeprazole | Omeprazole | 278 | 51 |
| Synthroid | Levothyroxine Sodium | 272 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 265 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 35 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 226 | 41 |
| Alendronate Sodium | Alendronate Sodium | 213 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 38 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 203 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 183 | 30 |
| Losartan Potassium | Losartan Potassium | 182 | 28 |
| Ezetimibe | Ezetimibe | 178 | 27 |
| Gabapentin | Gabapentin | 166 | 34 |
| Temazepam | Temazepam | 152 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 27 |
| Fenofibrate | Fenofibrate | 137 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 20 |
| Diclofenac Potassium | Diclofenac Potassium | 132 | 52 |
| Jentadueto | Linagliptin/Metformin Hcl | 115 | 16 |
| Ramipril | Ramipril | 108 | 15 |
| Jardiance | Empagliflozin | 107 | 20 |
| Lansoprazole | Lansoprazole | 104 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | 16 |
| Allopurinol | Allopurinol | 93 | 13 |
| Simvastatin | Simvastatin | 93 | 13 |
| Furosemide | Furosemide | 90 | 16 |
| Etodolac Er | Etodolac | 86 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 12 |
| Carvedilol | Carvedilol | 79 | 16 |
| Irbesartan | Irbesartan | 79 | 14 |
| Clonazepam | Clonazepam | 74 | 16 |
| Meloxicam | Meloxicam | 74 | 21 |
| Latanoprost | Latanoprost | 68 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 16 |
| Spironolactone | Spironolactone | 62 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 22 |
| Baclofen | Baclofen | 56 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 12 |
| Donepezil Hcl | Donepezil Hcl | 54 | 11 |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Finasteride | Finasteride | 52 | suppressed |
| Nitroglycerin | Nitroglycerin | 52 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 51 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 19 |
| Indapamide | Indapamide | 50 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | suppressed |
| Cilostazol | Cilostazol | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 47 | suppressed |
| Nabumetone | Nabumetone | 45 | 11 |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 44 | 13 |
| Atenolol | Atenolol | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 39 | suppressed |
| Folic Acid | Folic Acid | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Prednisone | Prednisone | 31 | 23 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 29 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 28 | 14 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Lamictal | Lamotrigine | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | 12 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Orphenadrine Citrate | Orphenadrine Citrate | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,480.28 · 16 records | GlaxoSmithKline, LLC. | JARDIANCE, PENMENVY, SHINGRIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error